P
Paradigm Biocapital Advisors LP
+ HoldingIVA
-0.49%
3M Return
$3.110
+0.260 (+8.36%)At close
Loading chart…
- High
- 3.180
- Open
- 2.975
- VWAP
- 3.07
- Volume
- 2.91M
- Mkt Cap
- 154.47M
- Low
- 2.935
- Amount
- 8.94M
- EV/EBITDA, TTM
- -5.08
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
AI analysis of Inventiva SA (IVA)
BuyInventiva SA is a good buy right now due to its current price of $3.16, which is well below the analyst price target of $18 from Truist and $21 from Canaccord. The RSI is currently at 27.805, indicating that the stock is oversold, which could lead to a price rebound. Additionally, hedge funds have increased their buying activity by 681.82% over the last quarter, suggesting strong institutional interest. The main risk is the company's negative earnings with a P/E ratio of -1.31, indicating ongoing financial challenges that could impact future performance.
Valuation Metrics
The current forward P/E ratio for Inventiva SA (IVA) is 0.00, compared to its 5-year average forward P/E of -4.05.
Whales holding IVA
Events Timeline
News
9.509-28NASDAQ.COMInventiva Reports Significant Improvement in H1 2026 Financial Results
9.507-29seekingalphaInventiva S.A. 1H 2026 Financial Overview
8.506-02NASDAQ.COMInventiva S.A. Halts Trading for Financing
- 9.505-27seekingalpha
Inventiva S.A. Reports No Revenue for Q1 2026
- 9.503-30seekingalpha
Inventiva S.A. Reports FY GAAP EPS and Revenue Decline
IVA FAQ — answered by Alphio AI
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology. It operates in the Healthcare sector.
Inventiva SA is a good buy right now due to its current price of $3.16, which is well below the analyst price target of $18 from Truist and $21 from Canaccord. The RSI is currently at 27.805, indicating that the stock is oversold, which could lead to a price rebound. Additionally, hedge funds have increased their buying activity by 681.82% over the last quarter, suggesting strong institutional interest. The main risk is the company's negative earnings with a P/E ratio of -1.31, indicating ongoing financial challenges that could impact future performance.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.